Introduction
In an article published in Health Affairs in 2006, Grabowski and Wang (G&W) examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 to 2003 1 . Although there is a well documented decline over time in total worldwide introductions, we found various quality indicators such as the number of global, first-in-class, biotech and orphan drugs exhibited more positive trends. U.S. headquartered firms also assumed a strong leadership position in terms of being the initial introducers of the most novel compounds including first-in-class, biotech and orphan drugs.
In this paper, I provide a complementary analysis to our earlier paper by focusing on the drug discovery stage across each of these regions. Multinational firms perform research and develop new drugs in several locations. Firms also enter partnering and licensing agreements involving new drug candidates, so the nationality of a firm introducing a product is often different from the one where the drug was invented and initially developed. There is also a well-defined and studied "market for innovation" in pharmaceuticals 2 . This is especially true in the biotech industry which has been the source of many novel products over the past two decades. I utilize information contained in patent data to establish the region of discovery for all the first-in-class, biotech, global and orphan compounds in the G&W sample. These data show that R&D labs located in the U.S. have discovered more products in these categories than R&D labs based in Europe or Japan. U.S. leadership also has increased over time. These findings are consistent with other studies using different samples and indicators of drug discovery by countries and geographical regions.
In the next section, I summarize prior literature and discuss the rationale for utili zing first-in-class, biotech, global and orphan drugs as measures of drug quality. In the following sections, I present the empirical findings on the location of pharmaceutical discoveries in the United States, Europe and Japan for each of these drug quality measures. A subsequent section also considers several issues surrounding an analysis of R&D productivity by region by Light that utilizes our data on new drug introductions 3 . The final section offers some observations on the policy implications of the analyses on international competitiveness undertaken here and in related studies.
Drug quality measures in the prior literature
In examining international data on innovative performance, various scholars and research organizations historically examined different output and input measures, such as new drug introductions, patent counts, and research and development expenditures 4 . While these provide nice aggregate quantitative measures, they do not capture the quality of introductions over time or how quality indexed introductions compare across countries.
A quality-oriented index that began receiving attention by scholars in the 1980s was the concept of consensus or global new chemical entities (NCEs) 5 . Global NCEs are defined as new drugs introduced into a majority of the world's leading drug markets. Several scholars noted that a large percentage of drug introductions historically were introduced into one or a few closely related countries. Global NCEs capture important therapeutic advances from a medical perspective as well as drugs that address significant market opportunities. In this regard, Grabowski (1989) found that although there were over 50 annual NCEs introduced internationally from the 1970s through 1983, only 24 percent of these were introduced into a majority of the world's largest markets.
In my study with Richard Wang, we considered global introductions as one index of drug quality, but developed some alternative measures that reflect other specific quality attributes. We gave particular attention to drug novelty or first-in-class drugs. In addition, we examined trends in and sources of biotech drugs and orphan compounds given that these entities often provide therapeutic advances for illnesses and disabilities with substantial unmet medical needs.
Sample Scope and Definitions in Grabowski and Wang's Analysis
The current analysis builds on Grabowski and Wang's sample and methodology to examine the country of discovery. In this section, a brief summary of the underlying data source is provided. The definition of globe introductions in the Grabowski and Wang study considers dissemination in the G7 countries (Canada, France, Germany, Italy, Japan, the United Kingdom and the United States). We defined global NCEs as those introduced in a majority (at least four) of the G7 countries. These countries are the world's seven largest pharmaceutical markets.
